论文部分内容阅读
目的:探讨替罗非班联合急诊经皮冠状动脉介入治疗(PCI)治疗急性ST段抬高型心肌梗死的临床疗效。方法:2014年6月1日至2016年9月30日,选择英德市人民医院80例急性ST段抬高型心肌梗死患者进行研究,随机分组为两组,对照组采用急诊PCI治疗,治疗组:采用急诊PCI联合替罗非班治疗,比较两组患者的临床有效率、治疗后的冠状动脉造影血流分级(TIMI)血流分级情况、不良反应率。结果:(1)与对照组(75%)对比,观察组治疗有效率(95%)明显更高,差异具有统计学意义(P<0.05)。(2)与对照组对比,治疗组治疗后的TIMI 3级病例明显更多,差异具有统计学意义(P<0.05);两组TIMI 0级、1级、2级比较,差异均无统计学意义(P>0.05)。(3)两组患者治疗不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替罗非班联合急诊PCI治疗急性ST段抬高型心肌梗死的临床疗效更为显著,能够有效地改善患者心功能,并且不良反应没有明显增加,安全性良好。
Objective: To investigate the clinical efficacy of tirofiban combined with emergency percutaneous coronary intervention (PCI) in the treatment of acute ST-segment elevation myocardial infarction. Methods: From June 1, 2014 to September 30, 2016, 80 patients with acute ST-elevation myocardial infarction in Yingde People’s Hospital were selected and randomly divided into two groups. The control group was treated with emergency PCI Group: The emergency PCI combined with tirofiban treatment, clinical efficacy of two groups were compared, after treatment of coronary angiography grade (TIMI) blood flow grading, adverse reaction rate. Results: (1) Compared with the control group (75%), the effective rate of the observation group was significantly higher (95%), the difference was statistically significant (P <0.05). (2) Compared with the control group, TIMI level 3 after treatment in the treatment group was significantly more, the difference was statistically significant (P <0.05); There was no statistical difference between the two groups in TIMI 0, 1, 2 Significance (P> 0.05). (3) There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Tirofiban combined with emergency PCI in the treatment of acute ST-segment elevation myocardial infarction is more effective. It can effectively improve the cardiac function and has no significant increase in adverse reactions and good safety.